236
Views
5
CrossRef citations to date
0
Altmetric
Original Research

Prevalence of Multidrug-Resistant Tuberculosis in Dalian, China: A Retrospective Study

ORCID Icon, , , , , , ORCID Icon, , , , & show all
Pages 1037-1047 | Published online: 16 Mar 2021

References

  • World Health Organization. Global Tuberculosis Report 2020. Geneva: World Health Organization; 2020.
  • Miotto P, Zhang Y, Cirillo DM, Yam WC. Drug resistance mechanisms and drug susceptibility testing for tuberculosis. Respirology. 2018;23(12):1098–1113.30189463
  • Knight GM, McQuaid CF, Dodd PJ, Houben R. Global burden of latent multidrug-resistant tuberculosis: trends and estimates based on mathematical modelling. Lancet Infect Dis. 2019;19(8):903–912.31281059
  • Lv XT, Lu XW, Shi XY, Zhou L. Prevalence and risk factors of multi-drug resistant tuberculosis in Dalian, China. J Int Med Res. 2017;45(6):1779–1786.28345426
  • Yao S, Yan J, Li L, et al. Determining Mycobacterium tuberculosis drug resistance and risk factors for multidrug-resistant tuberculosis in sputum smear-positive tuberculosis outpatients in Anhui Province, China, 2015-2016. Infect Drug Resist. 2020;13:1023–1032.32308444
  • Feng M, Xu Y, Zhang X, et al. Risk factors of multidrug-resistant tuberculosis in China: a meta-analysis. Public Health Nurs. 2019;36(3):257–269.30680796
  • Pradipta IS, Forsman LD, Bruchfeld J, Hak E, Alffenaar JW. Risk factors of multidrug-resistant tuberculosis: a global systematic review and meta-analysis. J Infect. 2018;77(6):469–478.30339803
  • Liao S, Cai C, Huo FM, et al. Trends in drug-resistant tuberculosis in China: data from a clinical tuberculosis centre. Int J Tuberc Lung Dis. 2017;21(9):990–995.28826447
  • Ma Y, Pang Y, Du J, Liu Y, Li L, Gao W. Clinical outcomes for multi- and extensively drug resistant tuberculosis patients with adjunctive resectional lung surgery in Beijing, China. J Thorac Dis. 2017;9(3):841–845.28449494
  • Ding P, Li X, Jia Z, Lu Z. Multidrug-resistant tuberculosis (MDR-TB) disease burden in China: a systematic review and spatio-temporal analysis. BMC Infect Dis. 2017;17(1):57.28073344
  • Liao S, Cai C, Huo FM, et al. Trends in drug-resistant tuberculosis in China: data from a clinical tuberculosis centre. 2017;21(9):990.
  • Zhang J, Gou H, Hu X, et al. Status of drug-resistant tuberculosis in China: a systematic review and meta-analysis. Am J Infect Control. 2016;44(6):671–676.26944006
  • Duan Q, Chen Z, Chen C, et al. The prevalence of drug-resistant tuberculosis in mainland china: an updated systematic review and meta-analysis. PLoS One. 2016;11(2):e0148041.26859846
  • He XC, Zhang XX, Zhao JN, et al. Epidemiological trends of drug-resistant tuberculosis in China From 2007 to 2014: a retrospective study. Medicine (Baltimore). 2016;95(15):e3336.27082586
  • Ding C, Wang S, Shangguan Y, et al. Epidemic trends of tuberculosis in China from 1990 to 2017: evidence from the global burden of disease study. Infect Drug Resist. 2020;13:1663–1672.32606817
  • Falzon D, Jaramillo E, Schunemann HJ, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J. 2011;38(3):516–528.21828024
  • World Health Organization. Treatment of Tuberculosis Guidelines. Geneva, Switzerland; 2009.
  • Luo D, Chen Q, Xiong G, et al. Prevalence and molecular characterization of multidrug-resistant M. tuberculosis in Jiangxi province, China. Sci Rep. 2019;9(1):7315.31086215
  • Lin M, Zhong Y, Chen Z, et al. High incidence of drug-resistant Mycobacterium tuberculosis in Hainan Island, China. Trop Med Int Health. 2019;24(9):1098–1103.31278806
  • Dheda K, Gumbo T, Maartens G, et al. The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. Lancet Respir Med. 2017.
  • Yang C, Luo T, Shen X, et al. Transmission of multidrug-resistant Mycobacterium tuberculosis in Shanghai, China: a retrospective observational study using whole-genome sequencing and epidemiological investigation. Lancet Infect Dis. 2017;17(3):275–284.27919643
  • Keller PM. Urban transmission of tuberculosis in China. Lancet Infect Dis. 2018;18(7):706–707.29681518
  • Yang C, Lu L, Warren JL, et al. Internal migration and transmission dynamics of tuberculosis in Shanghai, China: an epidemiological, spatial, genomic analysis. Lancet Infect Dis. 2018;18(7):788–795.29681517
  • Al-Ghafli H, Kohl TA, Merker M, et al. Drug-resistance profiling and transmission dynamics of multidrug-resistant Mycobacterium tuberculosis in Saudi Arabia revealed by whole genome sequencing. Infect Drug Resist. 2018;11:2219–2229.30519060
  • Marais BJ, Sintchenko V. Epidemic spread of multidrug-resistant tuberculosis in China. Lancet Infect Dis. 2017;17(3):238–239.27919642
  • Zewdie O, Dabsu R, Kifle E, Befikadu D. Rifampicin-resistant multidrug-resistant tuberculosis cases in selected hospitals in Western Oromia, Ethiopia: cross-sectional retrospective study. Infect Drug Resist. 2020;13:3699–3705.33116690
  • Zhang Y, Liu X, Yang L, et al. Barriers and strategies: a review of access to affordable multi-drug resistant tuberculosis medication in China. Infect Drug Resist. 2020;13:3679–3687.33116687
  • Mase SR, Chorba T. Treatment of drug-resistant tuberculosis. Clin Chest Med. 2019;40(4):775–795.31731984
  • Liu Y, Zhang X, Zhang Y, et al. Characterization of Mycobacterium tuberculosis strains in Beijing, China: drug susceptibility phenotypes and Beijing genotype family transmission. BMC Infect Dis. 2018;18(1):658.30547765
  • Anukool U, Phunpae P, Tharinjaroen CS, et al. Genotypic distribution and a potential diagnostic assay of multidrug-resistant tuberculosis in Northern Thailand. Infect Drug Resist. 2020;13:3375–3382.33061484
  • Suen SC, Bendavid E, Goldhaber-Fiebert JD. Disease control implications of India’s changing multi-drug resistant tuberculosis epidemic. PLoS One. 2014;9(3):e89822.24608234
  • Jenkins HE, Crudu V, Soltan V, Ciobanu A, Domente L, Cohen T. High risk and rapid appearance of multidrug resistance during tuberculosis treatment in Moldova. Eur Respir J. 2014;43(4):1132–1141.24558181
  • Espindola AL, Varughese M, Laskowski M, Shoukat A, Heffernan JM, Moghadas SM. Strategies for halting the rise of multidrug resistant TB epidemics: assessing the effect of early case detection and isolation. Int Health. 2017;9(2):80–90.28338827
  • Shen X, Yang CG, Wu JE, et al. Recurrent tuberculosis in an urban area in China: relapse or exogenous reinfection? Tuberculosis. 2017;103:97–104.28237039
  • Song WM, Li YF, Ma XB, et al. Primary drug resistance of mycobacterium tuberculosis in Shandong, China, 2004-2018. Respir Res. 2019;20(1):223.31627757
  • An Q, Song W, Liu J, et al. Primary drug-resistance pattern and trend in elderly tuberculosis patients in Shandong, China, from 2004 to 2019. Infect Drug Resist. 2020;13:4133–4145.33223840
  • Gurjav U, Burneebaatar B, Narmandakh E, et al. Spatiotemporal evidence for cross-border spread of MDR-TB along the Trans-Siberian Railway line. Int J Tuberc Lung Dis. 2015;19(11):1376–1382.26467591
  • Ahmed M, Mishra A, Sawlani KK, et al. Clinical predictors of streptomycin-vestibulotoxicity. Indian J Otolaryngol Head Neck Surg. 2016;68(3):359–366.27508140
  • Consensus Guidelines APITB. Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations. J Assoc Physicians India. 2006;2006(54):219–234.
  • Abbadi SH, Sameaa GA, Morlock G, Cooksey RC. Molecular identification of mutations associated with anti-tuberculosis drug resistance among strains of Mycobacterium tuberculosis. Int J Infect Dis. 2009;13(6):673–678.19138546
  • Jou R, Chiang CY, Yu CY, Wu MH. Proficiency of drug susceptibility testing for Mycobacterium tuberculosis in Taiwan. Int J Tuberculosis Lung Dis. 2009;13(9):1142–1147.